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Abstract— A focused library of TX-67 (C10 hemi-succinate) analogs have been prepared including regioisomeric, functional group, and 
one-carbon homologs.  These were prepared to investigate TX-67’s lack of interaction with P-glycoprotein (Pgp).  Tubulin stabilization 
ability, cytotoxicity, and Pgp interactions were evaluated.  All carboxylic acid analogs had no apparent interactions with Pgp whereas the 
ester variants of the same compounds displayed characteristics of Pgp substrates.  Furthermore, it is demonstrated that hydrogen-bonding 
properties were significant with respect to Pgp interactions.  This anionic introduction strategy may allow for delivery of paclitaxel into 
the CNS as well as establishing a new method for delivery of other, non-CNS permeable drugs.    
Paclitaxel (Taxol, 1, Figure 1), a structurally complex 
natural product derived from the bark of the Pacific 
Yew, is one of the most studied and active anti-cancer 
agents known.1,2 Although its clinical success is 
remarkable, the efficacy of the parent compound has 
limitations.3   
 
 
Figure 1.  Paclitaxel  and docetaxel 
 
One such shortcoming is paclitaxel’s inability to cross 
the blood-brain barrier (BBB).4  Accordingly, paclitaxel 
is not an effective treatment for primary or metastatic 
brain cancer despite its potent anti-proliferative activity.  
In addition to paclitaxel’s well known anti-tumor 
properties, it has been shown to protect primary cortical 
neurons from beta amyloid (A)-induced cell death as 
well as being non-toxic to primary cortical neurons.5 
Indeed, a paclitaxel derivative that could permeate the 
CNS is highly desirable from both the standpoint of 
chemotherapy as well as an investigational therapy for 
neurofibrillary pathology.   
 
A primary mechanism limiting the distribution of 
paclitaxel and other highly lipophillic substances into 
the brain is active efflux by the multidrug resistant gene 
product 1 (MDR1) P-glycoprotein (Pgp).4 We have 
recently described a series of recognition elements 
required for Pgp interactions based upon the analysis of 
over one hundred known Pgp substrates.6,7 This analysis 
revealed clusters of spatially distinct hydrogen bond 
acceptor units which correlated, in their relative 
frequency, with the strength of Pgp interaction.  We 
have demonstrated that deletion or modification of these 
“recognition elements” in paclitaxel reduces interaction 
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with Pgp in bovine brain microvessel endothelial cells.8 
These studies also bolstered our ascertation that the C10 
region of paclitaxel was particularly important for Pgp 
affinity.  
This same examination of known Pgp substrates also 
revealed that compounds that carry a negative charge at 
physiological pH, such as those that contain a 
carboxylic acid, sulphonate, or nitro group, with few 
exceptions, are not substrates for Pgp efflux.6,7 One 
caveat to this observation was that chemical structures 
that contain additional recognition elements, maintain 
their affinity for Pgp. 
 
Figure 2.  TX-67 recognition and repulsion elements 
 
With this in mind we prepared a C-10 modified taxane, 
TX-67 (3, Figure 2), which only differs from paclitaxel 
by the addition of an acetic acid unit to the terminus of 
the C10 acetyl ester.9 TX-67 (3) contains all of the 
recognition elements of paclitaxel, however, our studies 
suggest Pgp efflux mechanisms are substantially 
reduced or absent completely.9,10 Compound 3 
demonstrates improved distribution across the BBB 
without co-administration of Pgp inhibitors both in vitro 
and in situ.     
 
Herein we describe the synthesis and biological 
evaluation of a focused library of TX-67 analogs 
including functional group, regioisomeric, and one-
carbon homologs. These were made to determine if the 
acid functionality was essential for Pgp evasion and if 
this phenomenon was restricted to only C10 analogs. 
 
 
Scheme 1.  Synthesis of C10 TX-67 analogs.  Reagents and conditions: 
(a) succinic anhydride, DMAP, toluene 85 oC; (b) glutaric anhydride, 
DMAP, toluene 85 oC; (c) CH2N2, THF; (d) NH4CO3, THF, BOC2O, 
pyridine; (e) NH2Me
.HCl, EDCI, NMM, CH2Cl2; (f) NHMe2
.HCl, EDCI, 
NMM, CH2Cl2;  (g) HF-pyridine, pyridine. 
 
The C10 functional group analogs are prepared from 
common intermediate 4 (Scheme 1).  TX—67 (3) was 
prepared as previously descried while compounds 7-10 
were accessed via the protected variant (5).  Acid 5 is 
cleanly and quantitatively converted to the methyl ester 
via treatment with diazomethane (Scheme 1), which, 
after treatment with HF-pyridine solution provides 
methyl ester 7 in good yield.  The primary amide analog 
8 is prepared via mixed anhydride formation with 
BOC2O followed by amide formation via ammonium 
bicarbonate (NH4CO3) under basic conditions.  The N-
methyl and N,N-dimethyl, amides (9 and 10) are 
generated via standard coupling procedures.  The 
described functional group transformations were each 
followed by fluoride anion assisted protecting group 
removal.  Compounds 11-14 were prepared in the same 
manner from glutaric acid derivative 6. 
Scheme 2.  Synthesis of C7 TX-67 analogs.  Reagents and conditions: (a) 
succinic anhydride, DMAP, toluene 85 oC; (b) glutaric anhydride, DMAP, 
toluene 85 oC; (c) MeOH, EDCI, DMAP; (d) NH4CO3, THF, BOC2O, 
pyridine; (e) NH2Me
.HCl, EDCI, NMM, CH2Cl2; (f) NHMe2
.HCl, EDCI, 
NMM, CH2Cl2;  (g) HF-pyridine, pyridine 
 
The desired C7 analogs are accessed in short synthetic 
sequences from common intermediate 15 (Scheme 2).  
The C7 succinnic acid analog 18 is prepared by 
acylating the C7 hydroxyl group with succinic 
anhydride, giving 16, followed by removing the 
2’OTBS protecting group.  The methyl ester analog (19) 
is generated from a coupling between acid 16 and 
MeOH followed by the same deprotection.  The 
remaining compounds (21-26) were synthesized as 
described for the C10 analogs. 
 
Table 1. ED50 ratios (compound/paclitaxel) for in vitro tubulin assembly 
and cytoxicity. 
Entry Compound
Tubulin 
Assembly MCF7
NCI/ADR-
RES
1 paclitaxel (1) 1.0 1.0 1.0
 
2 TX-67 (3 – C10 CO2H) 1.7 13.3 1.3
3 C10 CH2CO2H (11) 1.8 27.9 5.8
4 C7 CO2H (18) 3.8 >30.0 5.8
5 C7 CH2CO2H (23) 1.0 8.8 13.6
 
6 C10 CO2Me (7) 1.0 2.5 0.4
7 C7 CO2Me (19) 1.2 0.54 0.5
 
8 C10 CONH2 (8) 0.4 10 6.0
9 C10 CH2CONH2 (12) 1.8 10 5.3
10 C7 CONH2 (20) 0.6 3.2 0.6
11 C7 CH2CONH2 (24) 0.6 5.0 6.5
 
12 C10 CONHMe (9) 0.8 7.9 6.0
13 C10 CH2CONHMe (13) 1.8 2.3 >6.3
14 C7 CONHMe (21) 0.8 2.2 1.0
15 C7 CH2CONHMe (25) 0.8 3.7 3.2
 
16 C10 CONMe2 (10) 1.6 2.1 2.7
17 C10 CH2CONMe2 (14) 2.2 5.6 >6.3
18 C7 CONMe2 (18) 1.1 10.8 0.8
19 C7 CH2CONMe2 (26) 0.7 3.9 3.0
Paclitaxel has a mean ED50 of 3.23 nM ± 1.84 and 1.53 M ± 1.26 in the 
MCF-7 and NCI/ADR-RES lines, respectively. 
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Table 2.  Rhodamine uptake results for compounds 1 (paclitaxel), C10 and C7 acids (3, 11, 18 and 23), C10 and C7 esters (7 and 19), C10 and C7 primary 
amides (8, 12, 20 and 24), C10 and C7 secondary amides (9, 13, 21, and 25), and C10 and C7 tertiary amides (10, 14, 18, and 26) in BMEC’s.  Paclitaxel 
and the derivatives were present at a concentration of 10 M.  The concentration of rhodamine was 5M. 
 
All compounds were first evaluated for tubulin 
assembly ability as well as effectiveness against 
cancer cell lines (Table 1).  These cell lines included 
the MCF7 breast cancer cell line and a drug resistant 
breast cancer cell line (NCI/ADR-RES). 
  
In the tubulin assembly assay, all analogs maintained 
similar activity to the parent compound (entries 2-19, 
table 1). Against the MCF7 breast cancer cell line 
most analogs maintained effectiveness.  The 
carboxylic acid analogs (entries 2-5), as a functional 
group class, showed the largest drop in activity 
(approx. 20 fold). The methyl ester variants (entries 6 
and 7) maintained similar potency as compared to 
paclitaxel while the amides (entries 8-19) generally 
experienced an approximate 5-fold reduction in 
cytotoxicity.  Versus the breast cancer cell line 
(NCI/ADR-RES) most analogs performed similar to 
paclitaxel.  We had originally hypothesized an 
increase in effectiveness of these analogs against the 
MDR breast cancer cell line (MCF7-ADR [Pgp over-
expressing]) however this was not the case.11  
 
Our next biological screen was the rhodamine 123 
uptake assay (Table 2).12  This assay is a preliminary 
screen to evaluate a compounds interaction with Pgp 
in bovine brain microvessel endothelial cells 
(BMECs).  In this assay, rhodamine 123 is used as a 
surrogate Pgp substrate.  The effect of the test 
compound on rhodamine 123 is determined by 
monitoring intracellular fluorescence.  If the test 
compound is a substrate for Pgp, then addition of it  
will increase rhodamine 123 uptake relative to the 
negative control. 
 
All analogs containing a carboxylic acid functionality 
(3, 11, 18 and 23) showed no apparent interaction with 
Pgp.  When the carboxylic acid is capped with a 
methyl group (7 and 19), in both the C7 and C10 
series, a marked increase in rhodamine accumulation 
is observed.   This supports our hypothesis that the 
carboxylic acid functionality is required to evade Pgp.  
To our surprise, many members of the amide series (8-
10, 12-14, 20, 21 and 24), did not significantly 
increase rhodamine accumulation.  These examples 
are contrary to our suggestion that an anion is required 
and indicates that other factors are involved in 
recognition by Pgp.  As the amide is converting from a 
hydrogen bond donor (8, 9, 12, 13, 20, 21 and 25) to a 
hydrogen bond acceptor (10, 14, 18 and 26), we see 
transformation from a molecule that shows little 
interactions with Pgp to one which is an apparent 
substrate.  This is in accord with our hypothesis that 
H-bond donors will not interact with Pgp and H-bond 
acceptors will serve as substrates.  This implies that 
the C10 region on these analogs has a very intimate 
relationship with Pgp.  Additionally, it is worth noting 
that succinate-like modifications made at the C7 
position were more likely to result in an increase in 
Pgp interaction that the same modifications at the C10 
position.  This effect was substantial in the N-methyl 
amide series (10, 14, 18, and 26) but minor in the 
methyl ester series (7 and 19).  Interestingly, this trend 
did not hold up in the primary amide series (8, 12, 20, 
and 24).  Furthermore, in all cases except amides 18 
and 26, the succinic acid derivatives showed less Pgp 
interaction than their glutaric acid counterparts. These 
data further suggest that groups added to decrease Pgp 
interactions may be more effective at the C10 position 
on the paclitaxel structure. 
 
We have prepared a focused library of paclitaxel 
analogs in short synthetic sequences from the parent 
molecule.  Biological evaluation in tubulin 
stabilization and cytotoxicity assays demonstrate our 
designed analogs maintain the desired properties of 
paclitaxel.  Our rhodamine assay indicates that the 
placement of a carboxylic acid functionality on either 
the C7 or C10 position diminishes interactions with 
Pgp found in bovine BBB.  Since carboxylic acid 
transporters are known to exist in the BBB, it should 
be considered that the carboxylic acid functionality is 
a substrate for an influx pump, in a similar fashion that 
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paclitaxel acts as a substrate for cellular efflux.  It is 
possible that this influx transport system is shuttling 
TX-67 into the cell, past the Pgp efflux system, 
allowing for the observed increase in BBB 
permeation.  Current studies are underway to 
determine if other paclitaxel analogs containing 
carboxylic acid functionalities are capable of increased 
permeation across the BBB.  Furthermore, we have 
illustrated that the length of linker between paclitaxel 
and the functional group can be modified with little 
effect.  Unexpectedly, we have uncovered that the acid 
functionality is not required in all cases and that 
hydrogen bonding character of the particular analog 
plays a significant role. This anionic introduction 
strategy may allow for delivery of paclitaxel into the 
CNS as well as establishing a new tactic for delivery 
of other, non-CNS permeable drugs.    
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